Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06384573 · ClinicalTrials.gov registry record · Phase 3

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 3
Development phase
40
Enrollment target
6
Study locations

NCT06384573 is a Phase 3 study of Dementia and Alzheimers Disease that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 40 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06384573, a Phase 3 study of Dementia and Alzheimers Disease, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
40 participants
Enrollment target
6
Study locations

Study Summary

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.

Conditions Studied

Dementia Alzheimers Disease Alzheimers Disease, Familial

Interventions

  • DRUG lecanemab

Study Locations (6)

Alabama

  • University of Alabama in Birmingham - Birmingham

Indiana

  • Indiana University School of Medicine - Indianapolis

Missouri

  • Washington University in St. Louis - St Louis

Washington

  • University of Washington - Seattle

New South Wales

  • Neuroscience Research Australia - Randwick

Greater London

  • The National Hospital for Neurology and Neurosurgery - London

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-06-10
Est. Completion 2030-06
Phase Phase 3

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06384573

The ClinicalTrials.gov registry entry for NCT06384573 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which lecanemab is the first listed.

NCT06384573 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, Indiana, Missouri.

Frequently Asked Questions

What is clinical trial NCT06384573 about?

NCT06384573 is a clinical study titled "DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease". This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to exter...

What is the current status of trial NCT06384573?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2024-06-10. Estimated completion is 2030-06.

What conditions does trial NCT06384573 study?

This clinical trial studies the following conditions: Dementia, Alzheimers Disease, Alzheimers Disease, Familial.

What interventions are being tested in trial NCT06384573?

The interventions under investigation include: lecanemab (DRUG).

Who is sponsoring clinical trial NCT06384573?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06384573 being conducted?

This trial has 6 study locations across Alabama, Indiana, Missouri, Washington, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dementia

All registered trials for this condition

Alzheimers Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.